- Home
- PETZ vs CRIS Comparison
PETZ vs CRIS Comparison
Compare PETZ & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETZ | CRIS |
|---|---|---|
| Founded | 2002 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9M | 12.9M |
| IPO Year | 2017 | 2000 |
Fundamental Metrics
Financial Performance| Metric | PETZ | CRIS |
|---|---|---|
| Price | $1.11 | $0.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 15.5K | ★ 1.2M |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | $1,046,006.00 | ★ $11,650,000.00 |
| Revenue This Year | N/A | $6.13 |
| Revenue Next Year | N/A | $7.86 |
| P/E Ratio | $7.26 | ★ N/A |
| Revenue Growth | N/A | ★ 13.56 |
| 52 Week Low | $0.65 | $0.77 |
| 52 Week High | $1.68 | $3.57 |
Technical Indicators
Market Signals| Indicator | PETZ | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 69.39 | 41.62 |
| Support Level | $1.04 | $0.87 |
| Resistance Level | $1.20 | $0.96 |
| Average True Range (ATR) | 0.08 | 0.09 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 98.24 | 43.59 |
Price Performance
Historical ComparisonAbout PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling pet food and restaurant operations. The company has two operating segments, which include Petfood sales and the Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.